Medicare GLP-1 Coverage Drives 700,000 New Senior Users, Lilly Says

Eli Lilly's chief executive disclosed that approximately 700,000 Medicare-eligible seniors have initiated GLP-1 treatments since the federal program extended coverage for the blockbuster class of drugs in July, offering a fresh measure of how rapidly the policy change is reshaping access to obesity and diabetes medications.

Of those new patients, roughly 70 percent turned to Lilly's portfolio of GLP-1 therapies, a figure the company's CEO cited as evidence of the drugmaker's commanding position in a market that has drawn intense competition from rivals including Novo Nordisk.

Read more Google Fined Over €400M by Irish Regulator on Location Data →

The Medicare coverage expansion marks a significant policy shift that analysts had long anticipated would unleash substantial pent-up demand among older Americans who were previously unable to afford or access GLP-1 medicines. The new enrollment figures suggest that early uptake among seniors is materializing at a meaningful scale within just months of the program's launch.

The metrics also underscore the financial stakes involved for pharmaceutical manufacturers. GLP-1 drugs, which include treatments for Type 2 diabetes and weight management, have become among the fastest-growing product categories in the global pharmaceutical industry, and federal reimbursement adds a significant new patient pool to an already surging market.

The figures represent early data points in what industry observers expect will be a multiyear expansion as more seniors become aware of coverage options and physicians broaden prescribing practices. Continue reading at Business News.